Results 31 to 40 of about 351,529 (205)

Determination of potential genotoxic impurities in labetalol hydrochloride by HPLC-MS/MS method [PDF]

Journal of Hebei University of Science and Technology
In order to better control the potential genotoxic impurities in labetalol hydrochloride and ensure the safety of medication, a high-performance liquid chromatography-mass spectrometry(HPLC-MS/MS) method was established to detect potential genotoxic ...
Jiarui HAN, Yanmei XU, Lijuan HAO, Yanxia GAO   +3 more
doaj   +1 more source

Recent advances in self-targeting natural product-based nanomedicines

Journal of Nanobiotechnology
Natural products, recognized for their potential in disease prevention and treatment, have been integrated with advanced nano-delivery systems to create natural product-based nanomedicines, offering innovative approaches for various diseases.
Haifan Liu, Xingyue Jin, Suyi Liu, Xinyue Liu, Xiao Pei, Kunhui Sun, Meifang Li, Ping Wang, Yanxu Chang, Tiejie Wang, Bing Wang, Xie-an Yu   +11 more
doaj   +1 more source

Multi‐phase multi‐layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin

CPT: Pharmacometrics & Systems Pharmacology, 2022
Physiologically‐based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption, distribution, metabolism, excretion characteristics, formulation attributes, and trial design or ...
Nikunjkumar Patel, James F. Clarke, Farzaneh Salem, Tariq Abdulla, Frederico Martins, Sumit Arora, Eleftheria Tsakalozou, Arran Hodgkinson, Omid Arjmandi‐Tash, Sinziana Cristea, Priyanka Ghosh, Khondoker Alam, Sam G. Raney, Masoud Jamei, Sebastian Polak   +14 more
doaj   +1 more source

A Multichannel Fluorescent Array Sensor for Discrimination of Different Types of Drug-Induced Kidney Injury

Sensors, 2023
The differences in urinary proteins could provide a novel opportunity to distinguish the different types of drug-induced kidney injury (DIKI). In this research, Au nanoparticles–polyethyleneimine (AuNPs–PEI) and the three fluorophore-labeled proteins ...
Kunhui Sun, Bing Wang, Jiaoli Lin, Lei Han, Meifang Li, Ping Wang, Xiean Yu, Jiangwei Tian   +7 more
doaj   +1 more source

Delayed Access to Generic Medicine: A Comment on the Hatch-Waxman Act and the Approval Bottleneck [PDF]

, 2009
Prescription drug costs can be astronomical. The advent of generic drugs, which sell at substantially lower prices than their brand-name counterparts, can save consumers billions of dollars per year. The Hatch-Waxman Act, which governs the introduction
Patel, Ankur N.
core   +1 more source

Entry in the ADHD drugs market: Welfare impact of generics and me-toos [PDF]

, 2013
Recent decades have seen a growth in treatments for attention deficit hyperactivity disorder (ADHD) including many branded and generic drugs. In the early 2000's, new drug entry dramatically altered market shares.
Angell M., Barkley R. A., Bulow J., Conner D. F., Deaton A., FDAnews Drug Daily Bulletin, Frank R. G., Goozner M., Hausman J. A., Hausman J. A., Perwien A. R., Rector T. S., Safer D. J., Shulman S. R., Spencer T. J.   +14 more
core   +1 more source

Mechanistic modeling of drug products applied to the skin: A workshop summary report

CPT: Pharmacometrics & Systems Pharmacology, 2023
The development of a generic drug product involves demonstrating that there is no significant difference in the rate and extent to which the active ingredient becomes available at the site of action, relative to the reference listed drug product.
Eleftheria Tsakalozou, Khondoker Alam, Priyanka Ghosh, Jessica Spires, Sebastian Polak, Lanyan Fang, Srinivasa Sammeta, Ping Zhao, Sumit Arora, Sam G. Raney   +9 more
doaj   +1 more source

Pricing of drugs and donations: options for sustainable equity pricing. [PDF]

, 2001
Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines.
Ford, N, Herranz, E, Pérez-Casas, C
core   +2 more sources

Interchangeability of Generic Drugs: A Nonparametric Pharmacokinetic Model of Gabapentin Generic Drugs [PDF]

Clinical Pharmacology & Therapeutics, 2018
Substitution by generic drugs is allowed when bioequivalence to the originator drug has been established. However, it is known that similarity in exposure may not be achieved at every occasion for all individual patients when switching between formulations.
Glerum, Pieter J., Yu, Y., Yamada, Walter M., Neely, M.N., Maliepaard, M., Burger, D.M., Neef, C.   +6 more
openaire   +3 more sources

A survey of Top 200 Drugs—Inconsistent Practice of Drug Strength Expression for Drugs Containing Salt Forms [PDF]

, 2012
Many ionizable drugs are developed and marketed as salt forms. However, there are no clear US regulatory guidelines on drug strength labeling for salts. The strengths of some drugs are expressed as salts and some as free acids/bases.
Prohotsky, Daniel, Zhao, Fang
core   +2 more sources